The difficult cases often begin with a familiar contradiction: two patients follow comparable plans, yet their responses diverge.
Lifestyle, environment, medical history, existing conditions, and adherence can all contribute. Even after practitioners account for those factors, they may still lack part of the explanation.
Functional genomics offers another line of inquiry. Rather than treating each genetic variant as an isolated finding, it examines how groups of variants may influence connected biological pathways.
The DNA Company, based in Corona, California, developed DNA360™ to turn that systems-level view into an educational report for practitioners and consumers.
The Clinical Question Comes First
Personalized care begins with the individual, but the available information does not always explain the individual response.
A patient may follow a nutrition or lifestyle plan carefully and still respond differently from someone with similar goals. Another may report little benefit from an approach that appears useful elsewhere. Those differences do not make genetics the answer. They make genetics another possible source of context.
The practical question for a practitioner is not whether a gene determines an outcome. It is whether genetic information can reveal a pattern worth examining alongside the rest of the clinical picture.
From Variant Lists to Connected Systems
The DNA Company distinguishes DNA360 from reports that present isolated gene findings. Its systems-biology approach groups genetic associations across interconnected biological functions.
That structure changes the emphasis. Rather than treating one variant as a verdict, the report groups multiple findings by the biological pathways they may influence.
For example, DNA360 can present genetic factors associated with nutrient metabolism alongside pathways involved in methylation and detoxification. A practitioner can then consider those findings together, rather than reading each result as a separate instruction.
The report also covers areas associated with hormone processing, inflammatory response, neurotransmitter function, energy production, gut-related functions, and cellular maintenance.
This wider view may help practitioners identify relationships that an isolated result would not show. It still requires them to compare the report with the patient’s history, current condition, and other available information.
What DNA360 Is Designed to Support
The company says DNA360 supports educational conversations about nutrition, lifestyle, supplementation and other wellness strategies. Tracy Wood, CEO of The DNA Company shared, “The practitioner clinics we support are already spending hours creating individualized protocols. Through our new DNA360, these same clinics are beginning every patient relationship already knowing how they detoxify, methylate, process hormones, regulate inflammation, respond to stress, metabolize nutrients, and where their greatest inherited vulnerabilities lie. It changes every clinical conversation, and improves the health of the patient in alignment with how they were made.”
It also includes information about the genetic pathways involved in hormone metabolism and biological processes that may be relevant to discussions about hormone replacement therapy and peptide-based wellness approaches.
For a practitioner, that information may help organize a conversation. It may prompt a closer review of a standard recommendation, clarify a patient’s questions, or identify an area that deserves further assessment.
DNA360 is also designed to support patient education and practitioner workflows. Consumers can order DNA360, while practitioners can use it as part of a broader wellness discussion.
The report’s usefulness therefore depends on interpretation. A list of associations alone cannot account for the patient’s condition, environment, medications, behavior, or professional assessment.
Information, Not a Treatment Decision
DNA360 does not recommend, prescribe, diagnose, or determine whether any medical therapy is appropriate for an individual.
That limitation matters most when the report touches subjects such as hormones, peptides, supplements, or medications. Genetic information may inform a discussion, but it cannot establish safety, need, or likely response by itself.
The company’s own compliance language places those decisions with the individual and a licensed healthcare professional. This boundary also protects the value of the report. When DNA360 stays within its educational role, practitioners can judge the information for what it is: one input among many.
When genetic associations are presented as certainty, they can obscure rather than improve clinical judgment. The responsible use of functional genomics depends on resisting that leap.
What Supports the Interpretation
The DNA Company says its interpretation methods draw on peer-reviewed literature on gene function, biochemical pathways, and associated traits.
It also maintains an ongoing review of the literature. The company says it updates educational content and interpretive algorithms when emerging evidence materially changes an interpretation. “At The DNA Company, science is not static—and neither is our platform. Our educational content is continuously updated as new, scientifically vetted evidence becomes available. Our proprietary genomic interpretation algorithms integrate validated research across multiple biological pathways to convert complex DNA data into personalized, easy-to-understand reports with practical wellness insights that support more informed conversations and individualized health strategies,” said Wood.
Practitioner feedback and usability testing serve a different purpose. They can show whether the report communicates clearly and fits a working practice. They do not establish that every interpretation produces a clinical benefit. The company also cites internal audits and case reviews. Those processes can check whether interpretations remain consistent, plausible, and aligned with the evidence the company uses.
Laboratory controls belong in another category. Genetic assay validation measures the accuracy, precision, and reliability of the underlying test. It does not validate every conclusion drawn from the resulting data. Keeping those evidence categories separate helps practitioners understand what each one can support. Laboratory validation, literature review, internal quality checks, and practitioner experience answer different questions.
The company also acknowledges that practitioner observations do not replace clinical validation studies.
Genetics as Context, Not Destiny
DNA360 is available to both consumers and practitioners. That reach increases the need for careful explanation, especially when users expect a genetic report to deliver a definitive answer.
“Your genes are not diagnostic in a vacuum. They are not fatalistic,” Wood stated.
That principle gives the report its proper scale. A genetic association may suggest a tendency or point to a biological pathway. It cannot describe the whole person. The larger picture still includes health history, environment, current symptoms, laboratory findings, medications, behavior, and professional assessment.
For practitioners, the report may prove most useful when it sharpens the next question. It may help explain why an expected response did not occur or why a familiar approach deserves closer review. It should not close the inquiry. It should make the inquiry more informed.
Another Part of the Explanation
Functional genomics will not explain every unexpected response, and DNA360 does not replace clinical judgment. Its role is narrower: to organize genetic associations across connected pathways and provide another source of context for practitioners and patients.
That context may reveal questions that an isolated result would miss. It may also help practitioners explain why a broadly useful strategy still requires individual judgment.
The value lies not in promising a predetermined answer, but in helping the practitioner understand why the same plan may not produce the same result.
To learn more about The DNA Company and their genetic testing products visit thednacompany.com.
